ISOFOL MEDICAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.71 SEK | -2.07% |
|
-5.33% | -2.74% |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 766.1 | 647.5 | 2,334 | 1,492 | 119.5 | 117.9 |
| Enterprise Value (EV) 1 | 493.2 | 524.7 | 2,221 | 1,115 | -67.11 | -20.24 |
| P/E ratio | -9.19 x | -4.01 x | -9.11 x | -5.8 x | -0.75 x | -3.17 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 62,885,505 x | 66,604,305 x | 9,339,800 x | 163,531,583 x |
| EV / Revenue | - | - | 59,833,779 x | 49,743,681 x | -5,244,477 x | -28,074,520 x |
| EV / EBITDA | -5.5 x | -3.2 x | -11.9 x | -5.45 x | 0.4 x | 0.49 x |
| EV / FCF | -8.33 x | -6.08 x | -25.5 x | -9.69 x | 0.49 x | 0.49 x |
| FCF Yield | -12% | -16.4% | -3.93% | -10.3% | 206% | 205% |
| Price to Book | 2.89 x | 6.17 x | 35.1 x | 4.69 x | 0.75 x | 0.97 x |
| Nbr of stocks (in thousands) | 32,055 | 32,055 | 83,366 | 161,515 | 161,515 | 161,515 |
| Reference price 2 | 23.90 | 20.20 | 28.00 | 9.240 | 0.7400 | 0.7300 |
| Announcement Date | 4/11/19 | 6/2/20 | 5/14/21 | 4/27/22 | 4/6/23 | 4/16/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 37.12 | 22.41 | 12.8 | 0.721 |
| EBITDA 1 | -89.69 | -164.2 | -186.3 | -204.4 | -167.4 | -41.65 |
| EBIT 1 | -89.85 | -164.4 | -186.5 | -204.5 | -167.5 | -41.68 |
| Operating Margin | - | - | -502.42% | -912.51% | -1,308.59% | -5,781.41% |
| Earnings before Tax (EBT) 1 | -83.12 | -161.6 | -189 | -200.3 | -159.8 | -37.07 |
| Net income 1 | -83.12 | -161.6 | -189 | -200.3 | -159.8 | -37.07 |
| Net margin | - | - | -509.15% | -893.7% | -1,248.38% | -5,141.61% |
| EPS 2 | -2.600 | -5.041 | -3.075 | -1.594 | -0.9900 | -0.2300 |
| Free Cash Flow 1 | -59.2 | -86.27 | -87.22 | -115 | -138 | -41.54 |
| FCF margin | - | - | -234.98% | -513.15% | -1,078.71% | -5,761.41% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/11/19 | 6/2/20 | 5/14/21 | 4/27/22 | 4/6/23 | 4/16/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales | 5.154 | 4.704 | 4.007 | 4.027 | 2.907 | 1.915 | - | - |
| EBITDA | -51.81 | -62.46 | -49.14 | -56.76 | -34.76 | - | - | - |
| EBIT | -52.2 | -62.86 | -49.54 | -57.16 | -35.18 | -25.58 | - | - |
| Operating Margin | -1,012.9% | -1,336.27% | -1,236.46% | -1,419.29% | -1,210.11% | -1,335.82% | - | - |
| Earnings before Tax (EBT) 1 | -51.03 | -61.17 | -47.87 | -54.03 | -32.51 | -25.34 | -14.4 | -7.507 |
| Net income 1 | -51.03 | -61.17 | -47.87 | -54.03 | -32.51 | -25.34 | -14.4 | -7.507 |
| Net margin | -990.03% | -1,300.38% | -1,194.76% | -1,341.77% | -1,118.44% | -1,322.98% | - | - |
| EPS 2 | -0.3200 | -0.3800 | -0.3000 | -0.3300 | -0.2000 | -0.1600 | -0.0900 | -0.0500 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 2/24/22 | 5/12/22 | 8/23/22 | 11/11/22 | 2/22/23 | 5/3/23 | 8/22/23 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 273 | 123 | 113 | 378 | 187 | 138 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -59.2 | -86.3 | -87.2 | -115 | -138 | -41.5 |
| ROE (net income / shareholders' equity) | -27.3% | -87.4% | -220% | -104% | -67% | -26.5% |
| ROA (Net income/ Total Assets) | -17.3% | -47.2% | -79.1% | -46.5% | -34% | -14.9% |
| Assets 1 | 481 | 342.1 | 238.8 | 430.5 | 469.2 | 249.4 |
| Book Value Per Share 2 | 8.270 | 3.270 | 0.8000 | 1.970 | 0.9800 | 0.7500 |
| Cash Flow per Share 2 | 8.510 | 3.960 | 1.400 | 2.350 | 1.180 | 0.8600 |
| Capex | - | 0.32 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 4/11/19 | 6/2/20 | 5/14/21 | 4/27/22 | 4/6/23 | 4/16/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -2.74% | 10.91M | |
| +9.28% | 8.74B | |
| -15.14% | 4.94B | |
| +50.73% | 4.7B | |
| +4.36% | 3.98B | |
| -26.13% | 2.28B | |
| +12.07% | 2.28B | |
| +16.45% | 2.14B | |
| -33.59% | 2.12B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- ISOFOL Stock
- Financials Isofol Medical AB
